BioCardia: Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

 

• CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone
• Large sub-set of treated patients with elevated NTproBNP – a marker of heart distress – showed greater reductions, with 86% relative risk reduction in heart death equivalents and 24% relative risk reduction in non-fatal MACCE
• FDA-approved follow-on Phase III trial of high-responding patient population with elevated NTproBNP (CardiAMP HF II) has launched to validate positive interim results

https://www.biospace.com/article/releases/biocardia-reports-positive-interim-results-from-phase-iii-cardiamp-cell-therapy-heart-failure-trial-with-compelling-data-in-subgroup-with-elevated-ntprobnp-biomarker-for-heart-failure/